Small Cell Lung Cancer
Conditions
Brief summary
The purpose of this study is to evaluate the safety and efficacy of SHR-1316 in combination with Fluzoparib（SHR-3162） in Small Cell Lung Cancer Patients
Interventions
DRUG1.Experimental: A (Part 1): Fluzoparib and SHR -1316
1．Drug: Fluzoparib capsule will be given orally. Drug: SHR-1316 given intravenously (IV).
DRUG2.Experimental: B (Part 1): Fluzoparib and SHR -1316
2．Drug: Fluzoparib capsule will be given orally. Drug: SHR-1316 given intravenously (IV).
DRUG3.Experimental: C (Part 2): Fluzoparib and SHR -1316 Expansion
3．Drug: Fluzoparib capsule will be given orally. Drug: SHR-1316 given intravenously (IV).
Sponsors
Jiangsu HengRui Medicine Co., Ltd.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Patients must be at least 18 years of age. * Histologically or cytologically confirmed SCLC. * Failed at least one prior line of platinum-based chemotherapy. * Patients must have measurable disease as defined by RECIST v1.1. * ECOG 0-1. * Adequate hematologic and organ function * Signed inform consent form
Exclusion criteria
* Active or untreated central nervous system (CNS) metastases * Spinal cord compression not definitively treated with surgery and/or radiation . * Leptomeningeal disease * Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures * Malignancies other than SCLC within 5 years prior to randomization * History of autoimmune disease * Positive test result for human immunodeficiency virus (HIV) * Active hepatitis B or hepatitis C * Severe infections * Subjects with a condition requiring systemic treatment with either corticosteroids (\>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of first administration of study treatment. * Significant cardiovascular disease * Prior allogeneic bone marrow transplantation or solid organ transplant * Treatment with systemic immunosuppressive medications prior to randomization * Pregnant or lactating women * History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Part 1: 1.Number of Participants with AEs and SAEs | Up to approximately 24 months. |
| Part 1: 2. RP2D: Recommended dose for phase II study | Up to approximately 24 months. |
| Part 2: 1. ORR: Percentage of Participants With a CR or PR | Up to approximately 24 months. |
Secondary
| Measure | Time frame |
|---|---|
| Part 2: 3. DCR: Percentage of participants in the analysis population who have a CR, PR or SD per RECIST 1.1. | Up to approximately 24 months. |
| Part 1: 1. ORR: Percentage of Participants With a CR or PR | Up to approximately 24 months. |
| Part 2: 5. OS: Baseline until death from any cause | Up to approximately 24 months. |
| Part 2: 4. PFS: PFS is defined as the time from randomization to the first documented disease progression per RECIST 1.1 based on blinded independent central review or death due to any cause, whichever occurs first. | Up to approximately 24 months. |
| Part 2: 1.Number of Participants with AEs and SAEs | Up to approximately 24 months. |
| Part 2: 2.DoR: Percentage of Participants With a CR or PR | Up to approximately 24 months. |
Countries
China
Outcome results
None listed